Similar articles for PMID: 32613288

Year	Number of Results
2003	1
2011	2
2013	5
2014	4
2015	5
2016	4
2017	1
2018	2
2019	4
2020	51
2021	10
2022	3
2023	1
2024	0

1

Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.

Chalkias A, Mouzarou A, Samara E, Xanthos T, Ischaki E, Pantazopoulos I. Chalkias A, et al. Mol Diagn Ther. 2020 Oct;24(5):517-521. doi: 10.1007/s40291-020-00481-8. Mol Diagn Ther. 2020. PMID: 32613288 Free PMC article.

2

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Azam TU, et al. J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22. J Am Soc Nephrol. 2020. PMID: 32963090 Free PMC article.

3

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.

Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Rovina N, et al. Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4. Crit Care. 2020. PMID: 32354367 Free PMC article. No abstract available.

4

Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.

Lippi G, Henry BM, Favaloro EJ. Lippi G, et al. Clin Chem Lab Med. 2021 Jun 14;59(11):e413-e415. doi: 10.1515/cclm-2021-0561. Print 2021 Oct 26. Clin Chem Lab Med. 2021. PMID: 34116589 Free article. No abstract available.

5

COVID-19 and pneumonia: a role for the uPA/uPAR system.

D'Alonzo D, De Fenza M, Pavone V. D'Alonzo D, et al. Drug Discov Today. 2020 Aug;25(8):1528-1534. doi: 10.1016/j.drudis.2020.06.013. Epub 2020 Jun 18. Drug Discov Today. 2020. PMID: 32562843 Free PMC article. Review.

6

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.

Zhang Q, Li L, Chen H, Zhang G, Zhu S, Kong R, Chen H, Wang G, Sun B. Zhang Q, et al. J Clin Lab Anal. 2020 Mar;34(3):e23097. doi: 10.1002/jcla.23097. Epub 2019 Nov 27. J Clin Lab Anal. 2020. PMID: 31774228 Free PMC article.

7

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.

Stauning MA, Altintas I, Kallemose T, Eugen-Olsen J, Lindstrøm MB, Rasmussen LJH, Gamst-Jensen H, Nehlin JO, Andersen O, Tingleff J. Stauning MA, et al. J Emerg Med. 2021 Sep;61(3):298-313. doi: 10.1016/j.jemermed.2021.03.012. Epub 2021 Mar 26. J Emerg Med. 2021. PMID: 34092446 Free PMC article.

8

Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.

Oulhaj A, Alsuwaidi AR, Suliman A, Gasmelseed H, Khan S, Alawi S, Hukan Y, George J, Alshamsi F, Sheikh F, Babiker ZOE, Prattes J, Sourij H. Oulhaj A, et al. Int J Infect Dis. 2021 Jun;107:188-194. doi: 10.1016/j.ijid.2021.04.026. Epub 2021 Apr 20. Int J Infect Dis. 2021. PMID: 33862208 Free PMC article.

9

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.

Rasmussen LJH, Ladelund S, Haupt TH, Ellekilde GE, Eugen-Olsen J, Andersen O. Rasmussen LJH, et al. Crit Care Med. 2018 Dec;46(12):1961-1968. doi: 10.1097/CCM.0000000000003441. Crit Care Med. 2018. PMID: 30247244 Free PMC article.

10

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.

Sarif J, Raychaudhuri D, D'Rozario R, Bandopadhyay P, Singh P, Mehta P, Hoque MA, Sinha BP, Kushwaha M, Sahni S, Devi P, Chattopadhyay P, Paul SR, Ray Y, Chaudhuri K, Banerjee S, Majumdar D, Saha B, Sarkar BS, Bhattacharya P, Chatterjee S, Paul S, Ghosh P, Pandey R, Sengupta S, Ganguly D. Sarif J, et al. Front Immunol. 2021 Oct 28;12:738093. doi: 10.3389/fimmu.2021.738093. eCollection 2021. Front Immunol. 2021. PMID: 34777349 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

84 results

Results by year